Revista Espa?ola de Enfermedades Metabólicas óseas最新文献

{"title":"Estudio epidemiológico de factores de riesgo asociados a refractura en mujeres con fractura vertebral osteoporótica durante 10 años de seguimiento","authors":"R.J. García Renedo ,&nbsp;M. Mella Sousa ,&nbsp;M. Anaya Rojas ,&nbsp;J. Hernández Enríquez ,&nbsp;P. García Parra ,&nbsp;C. Fernández Pérez ,&nbsp;P. Cano Luis","doi":"10.1016/S1132-8460(09)73463-4","DOIUrl":"10.1016/S1132-8460(09)73463-4","url":null,"abstract":"<div><h3>Objetivos</h3><p>Los objetivos de este estudio son analizar las características epidemiológicas de las fracturas vertebrales osteoporóticas no quirúrgicas en mujeres, así como la posible relación que se da entre refractura y la existencia o no de tratamiento preventivo secundario contra la misma tras la primera fractura vertebral en un período de seguimiento de diez años.</p></div><div><h3>Métodos</h3><p>Se realiza un estudio de cohortes clínicas retrospectivas de un total de 77 mujeres con fractura vertebral osteoporótica no quirúrgica con un tiempo de seguimiento de diez años. Como variable dependiente se considera el riesgo de refractura y como variables independientes la edad al ingreso, el número de fracturas vertebrales osteoporóticas, los cambios en la actividad de la vida, el dolor de espalda, el tratamiento, el tratamiento previo con corticoides, las benzodiacepinas o psicotrópicos, el tabaco, el consumo de alcohol, el déficit estrogénico, el peso, la vida sedentaria, el déficit visual, la patología tiroidea y la dificultad para levantarse de la silla.</p></div><div><h3>Resultados</h3><p>El riesgo de nueva fractura vertebral o no vertebral a los 10 años tras la primera fractura es del 26%. Al comparar los riesgos de refractura atendiendo las características epidemiológicas, observamos que el porcentaje de refracturas aumenta con respecto al número de fracturas vertebrales en el primer episodio, siendo del 21,4% en el caso de una fractura vertebral, del 25,4% en el caso de dos fracturas vertebrales y del 50% cuando se trata de tres. La mayoría de las fracturas ocurren tras accidentes dentro de la rutina de la vida diaria. Sin embargo, no todos los pacientes experimentan un restablecimiento completo tras la fractura, ya que alrededor del 35% de estos enfermos sufren síntomas persistentes.</p></div><div><h3>Conclusiones</h3><p>Los factores relacionados estadísticamente con la refractura son la edad mayor de 70 años, la deprivación de estrógenos y la dificultad para levantarse de la silla. Las pacientes que han recibido tratamiento frente a la osteoporosis tras la primera fractura vertebral tienen menos riesgo de refractura (<em>odds ratio</em> [OR]: 0,32) con respecto al grupo que no ha recibido tratamiento alguno frente a la osteoporosis.</p></div><div><h3>Objectives</h3><p>This study has aimed to study the epidemiological characteristics of non-surgical osteoporotic vertebral fractures in women and the possible relationship existing between refracture and the existence or non-existence of secondary preventive treatment against it after the first vertebral fracture in a 10-year follow-up period.</p></div><div><h3>Methods</h3><p>A clinical retrospective study of cohorts of a total of 77 women with non-surgical osteoporotic vertebral fracture with a 10-year follow-up period was performed. The dependent variable was considered to be risk of refracture and independent variables as age on admission, number of osteoporotic vertebral fra","PeriodicalId":101109,"journal":{"name":"Revista Espa?ola de Enfermedades Metabólicas óseas","volume":"18 4","pages":"Pages 85-89"},"PeriodicalIF":0.0,"publicationDate":"2009-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1132-8460(09)73463-4","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134449433","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Osteopetrosis del adulto. Conceptos actuales","authors":"F.J. Cabrera Aguilar,&nbsp;A. Álvarez Perea,&nbsp;M. Gómez Antúnez,&nbsp;C. López González-Cobos,&nbsp;B. Pinilla Llorente,&nbsp;A. Muiño Míguez","doi":"10.1016/S1132-8460(09)73464-6","DOIUrl":"10.1016/S1132-8460(09)73464-6","url":null,"abstract":"<div><p>Se presentan cuatro casos de osteopetrosis del adulto, entidad poco frecuente, recogidos en nuestro hospital desde 1985 hasta 2005. Se revisa la patogenia y se actualizan conceptos y clasificación. Las manifestaciones clínicas se corresponden con otras publicaciones en las que la edad al diagnóstico es muy variable y el primer síntoma oscila desde dolor óseo a un hallazgo tras una fractura. Se revisan las mutaciones genéticas clásicas de todos los tipos, actualizando conceptos. Se introduce la propuesta de retirada de la osteopetrosis tipo I del adulto, ya que su patogenia parece un defecto intrínseco osteoblástico.</p></div><div><p>We presents four cases of adult osteopetrosis, a very rare disease, compiled from our hospital from 1985 to 2005. Revising the pathogenesis and updating the current concept and classification. The clinical manifestations correspond with other publications where the age at diagnosis is highly variable and the first symptom oscillate from bone pain to a fracture. Presents the classic genetic mutations of all types updating concepts. Introducing the propose withdrawal of adult osteoporosis type I, because the pathogenesis seemed a intrinsic osteoblastic defect.</p></div>","PeriodicalId":101109,"journal":{"name":"Revista Espa?ola de Enfermedades Metabólicas óseas","volume":"18 4","pages":"Pages 90-92"},"PeriodicalIF":0.0,"publicationDate":"2009-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1132-8460(09)73464-6","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"130389071","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Osteoporosis involutiva tipo i en la mujer posmenopáusica: diagnóstico y manejo clínico","authors":"E. González Jiménez ,&nbsp;J. Álvarez Ferre ,&nbsp;M.D. Pozo Cano ,&nbsp;M.C. Navarro Jiménez ,&nbsp;M.J. Aguilar Cordero ,&nbsp;J.M. Tristán Fernández","doi":"10.1016/S1132-8460(09)73462-2","DOIUrl":"10.1016/S1132-8460(09)73462-2","url":null,"abstract":"<div><p>La osteoporosis involutiva tipo I u osteoporosis posmenopáusica representa en la actualidad un importante problema de salud en el conjunto de los países desarrollados, afectando de manera especial a la mujer tras el período menopáusico en un 80% de casos. Un adecuado manejo clínico en cualquiera de los estadios del cuadro constituirá la herramienta esencial para alcanzar un óptimo seguimiento y abordaje de la enfermedad. Son numerosas las terapias a seguir como parte del esquema terapéutico de la enfermedad, sin embargo, el éxito de éstas pasa inexorablemente por un diagnóstico precoz. Todo ello con el fin de evitar las posibles y temidas complicaciones derivadas de la misma, entre las que caben destacar por su gravedad las fracturas óseas. Nuestro objetivo en esta revisión es ofrecer una actualización sobre los aspectos fisiopatológicos del cuadro, así como de los diferentes procedimientos terapéuticos existentes en la actualidad para su diagnóstico y abordaje clínico.</p></div><div><p>Type 1 involutional osteoporosis or postmenopausal osteoporosis is currently an important health problem in all developed countries. It especially affects 80% of postmenopausal women. An effective clinical management in any of the stages of this disease is essential to optimally approach and treat it. There are many treatment options to choose from as part of the therapeutic schema of the disease. However, the success of any of these treatments inexorably lies in an early diagnosis. This is crucial in the prevention of possible complications that can arise, such as bone fractures. This paper presents an update of the physiopathological aspects of osteoporosis, as well as the various therapeutic procedures currently used in its diagnosis and clinical approach.</p></div>","PeriodicalId":101109,"journal":{"name":"Revista Espa?ola de Enfermedades Metabólicas óseas","volume":"18 4","pages":"Pages 77-84"},"PeriodicalIF":0.0,"publicationDate":"2009-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1132-8460(09)73462-2","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"131977433","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Papel de la radioterapia en tumores óseos benignos de células gigantes","authors":"M.E. González-Domingo ,&nbsp;C. González-San Segundo ,&nbsp;M. Muñoz Fernández de Legaria","doi":"10.1016/S1132-8460(09)73460-9","DOIUrl":"10.1016/S1132-8460(09)73460-9","url":null,"abstract":"<div><p>El papel de la radioterapia (RT) en los tumores de células gigantes es incierto. El tratamiento estándar es la cirugía, y el uso de adyuvancia es controvertido. Tras la presentación de un caso clínico se analiza la indicación de la RT en estos tumores y se lleva a cabo una revisión retrospectiva, con historias clínicas de pacientes diagnosticados en el Hospital General Universitario Gregorio Marañón con informe de tumor de células gigantes, análisis y discusión de la literatura. En los tumores de células gigantes en los que éstos se presentan en localizaciones difíciles de realizar una resección amplia, la RT debe ser el tratamiento estándar posterior a la biopsia, alcanzando excelentes tasas de respuesta local. La RT de rescate tras recidiva proporciona una alta tasa de control local sin añadir una morbilidad importante, por lo que debería indicarse como tratamiento en los casos mencionados o como tratamiento paliativo.</p></div><div><p>The rol of the radiotherapy (RT) in the giant-cell tumor is unknown. The standart treatment is surgery and the use of adjuvant therapy is controversial. After a presentation of a clinical case, the indication of the RT is analyzed in these tumors, and a retrospective review is carried out with patients clinical histories diagnosed in the Hospital General Universitario Gregorio Marañón with report of tumor of giant cells, with analysis and discussion of the literature.</p><p>In giant cells tumors in which the tumor appears in locations difficult to realize a wide resection, the radiotherapy must be the standard treatment after biopsy, reaching excellent rates of local response. Rescue RT, after recurrence, provides a high rate of local control without adding an additional important morbidity, by it should be indicated as treatment in the mentioned cases or as palliative treatment.</p></div>","PeriodicalId":101109,"journal":{"name":"Revista Espa?ola de Enfermedades Metabólicas óseas","volume":"18 4","pages":"Pages 65-69"},"PeriodicalIF":0.0,"publicationDate":"2009-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1132-8460(09)73460-9","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"121246224","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clínica y diagnóstico diferencial de los hiperparatiroidismos","authors":"C. Gilsanz Fernández","doi":"10.1016/S1132-8460(09)73461-0","DOIUrl":"10.1016/S1132-8460(09)73461-0","url":null,"abstract":"<div><p>El hiperparatiroidismo se debe al incremento de la actividad de las glándulas paratiroides, que causa aumento de secreción o secreción inadecuada de hormona paratiroidea (PTH). El diagnóstico de hiperparatiroidismo se sospecha habitualmente por el hallazgo de hipercalcemia en analíticas de rutina. El hiperparatiroidismo primario tiene una incidencia anual aproximada de 20 casos por 100.000 habitantes. La mayor parte de los casos se deben a un único adenoma en una glándula paratiroidea; menos del 1% se debe a carcinomas paratiroideos. Los síntomas y signos del hiperparatiroidismo están relacionados más con la hipercalcemia que con el incremento de los niveles de PTH. El diagnóstico y el diagnóstico diferencial del hiperparatiroidismo se basan en las manifestaciones clínicas y en los niveles séricos de calcio y de PTH intacta. Los estudios de imagen, principalmente la ecografía de cuello y el rastreo con 99mTc sestamibi, ayudan en el diagnóstico y en la localización de adenomas.</p></div><div><p>Hyperparathyroidism is due to an increased activity of the parathyroid glands, leading to an inappropriate or overproduction of parathyroid hormone (PTH). The diagnosis of hyperparathyroidism is usually suspected by hypocalcaemia by routine serum calcium measurements. Primary hyperparathyroidism shows an annual incidence of approximately 20 cases per 100.000 habitants. Most cases are caused by a single adenoma of one the parathyroid glands; less than 1% of cases are related to a parathyroid carcinoma. Symptoms and clinical signs relate to chronic hypocalcaemia, rather than increased levels of hormone. Diagnosis and differential diagnosis of hyperparathyroidism is based in levels of serum calcium and intact PTH and symptoms and signs. Imaging studies, mainly neck ultrasound and 99mTc sestamibi scanning, help in diagnosis and localization of adenomas.</p></div>","PeriodicalId":101109,"journal":{"name":"Revista Espa?ola de Enfermedades Metabólicas óseas","volume":"18 4","pages":"Pages 70-76"},"PeriodicalIF":0.0,"publicationDate":"2009-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1132-8460(09)73461-0","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"130096569","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hipercalcemia como urgencia médica","authors":"J.A. Nuevo-González","doi":"10.1016/S1132-8460(09)73229-5","DOIUrl":"10.1016/S1132-8460(09)73229-5","url":null,"abstract":"<div><p>La hipercalcemia es una alteración del metabolismo del calcio que, producida bruscamente o por encima de 14,5<!--> <!-->mg/dl, puede provocar complicaciones sistémicas que comprometan la vida del paciente. Es una urgencia médica que se presenta con mayor frecuencia en la enfermedad tumoral avanzada, generalmente a través de la activación de la proteína relacionada con la hormona paratiroidea. Se debe iniciar un tratamiento inmediato, siendo la sueroterapia intensiva y los bifosfonatos intravenosos las claves para conseguir una restauración metabólica rápida. Zolendronato se considera actualmente el bifosfonato más eficaz para la hipercalcemia aguda.</p></div><div><p>Hypercalcemia is a metabolic disorder of calcium that may cause systemic complications when is produced suddenly or above 14.5<!--> <!-->mg/dl. It is considered as a medical emergency that appears more frequently at advanced malignant disease, usually through the activation of parathyroid hormone-related protein. It should be treated promptly and an intensive therapy with fluids and intravenous bisphosphonates are the keys to achieve metabolic restoration. At present, zoledronic acid is considered the most effective bisphosphonate for acute hypercalcemia.</p></div>","PeriodicalId":101109,"journal":{"name":"Revista Espa?ola de Enfermedades Metabólicas óseas","volume":"18 3","pages":"Pages 51-55"},"PeriodicalIF":0.0,"publicationDate":"2009-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1132-8460(09)73229-5","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"131907887","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tenofovir y enfermedad ósea en pacientes infectados por el VIH","authors":"A. Carrero,&nbsp;P. Ryan","doi":"10.1016/S1132-8460(09)73230-1","DOIUrl":"10.1016/S1132-8460(09)73230-1","url":null,"abstract":"<div><p>As a result of the introduction of high activity antiretroviral therapy (HAART), the situation of human immunodeficiency virus (HIV) infected patients has changed radically in developed countries. Both their survival and quality of life have improved. It is now when the long-term consequences, such as osteoporosis, of HIV infection are being communicated. There are many communications that refer to the greater prevalence of osteopenia and osteoporosis among these patients. Consequently, an increase in the number of osteoporotic fractures is to be expected. Among the mechanisms responsible for the loss of bone mass are the effect of HIV infection and antiretroviral therapy, this being a controversial subject of discussion that requires a greater number of studies. Herein, we review the osteoporosis in the HIV population, focusing on the risk factors and studies that involve antiretroviral treatment as an etiological agent and, fundamentally, tenofovir.</p></div>","PeriodicalId":101109,"journal":{"name":"Revista Espa?ola de Enfermedades Metabólicas óseas","volume":"18 3","pages":"Pages 56-62"},"PeriodicalIF":0.0,"publicationDate":"2009-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1132-8460(09)73230-1","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"103666647","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Metástasis óseas de cáncer de mama. Latencia durante 18 años","authors":"F.J. Nicolás-Sánchez,&nbsp;R.M. Sarrat-Nuevo,&nbsp;A. Roset Benito,&nbsp;S. Morales Murillo","doi":"10.1016/S1132-8460(09)73231-3","DOIUrl":"10.1016/S1132-8460(09)73231-3","url":null,"abstract":"","PeriodicalId":101109,"journal":{"name":"Revista Espa?ola de Enfermedades Metabólicas óseas","volume":"18 3","pages":"Page 63"},"PeriodicalIF":0.0,"publicationDate":"2009-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1132-8460(09)73231-3","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"131022421","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evolución de mujeres con osteoporosis tratadas durante más de tres años","authors":"J.A. Olmo Fernández-Delgado ,&nbsp;M. Canteras Jordana","doi":"10.1016/S1132-8460(09)73228-3","DOIUrl":"10.1016/S1132-8460(09)73228-3","url":null,"abstract":"<div><p>We are going to show the progress of 41 postmenopausal patients who have followed treatment for more than three years (86 months). Assessing several factors such as: development of the bone mineral density (BMD), adherence to therapeutic treatment, incidence of fractures and risk factors. Thirty five patients (85%) showed increases of the BMD in the spine with an average increase of 21%, and presented statistic changes (p<!--> <!-->&lt;<!--> <!-->0.005); 63% presented statistic changes in the hip but with not significant increases. Thirteen patients showed some fracture through fragility and 6 of them suffered more than one episode. By order of frequency: vertebral (spinal) fractures 8 (19.5%), radius 5 (12%), epiphysis of humerus 3 (7, 5%) and hip 2 (5%).</p><p>The most used treatment was alendronate (71%), followed by raloxifene (58%) and risedronate (54%). Using the Morisky test, the 48% of the patients were reliable.</p><p>We have found correlation between increases of the BMD and risk of fracture, not being found related to other risk factors.</p></div>","PeriodicalId":101109,"journal":{"name":"Revista Espa?ola de Enfermedades Metabólicas óseas","volume":"18 3","pages":"Pages 45-50"},"PeriodicalIF":0.0,"publicationDate":"2009-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1132-8460(09)73228-3","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"116161890","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Enfermedad de paget ósea: utilidad de los bifosfonatos como terapia","authors":"E. González Jiménez ,&nbsp;M.J. Aguilar Cordero ,&nbsp;P.A. García López ,&nbsp;R. Guisado Barrilao ,&nbsp;J. Álvarez Ferre ,&nbsp;C.A. Padilla López","doi":"10.1016/S1132-8460(09)72052-5","DOIUrl":"10.1016/S1132-8460(09)72052-5","url":null,"abstract":"<div><p>La enfermedad de Paget ósea constituye un cuadro clínico patológico caracterizado por la aparición y desarrollo de lesiones óseas dotadas de una acelerada actividad ósea resortiva y a la que se superpone un proceso de síntesis osteoblástica de igual o similar intensidad aunque de características desorganizadas.</p><p>El desarrollo paralelo de un intenso remodelado óseo hace necesaria la utilización clínica de fármacos con capacidad antirresortiva, dentro de los cuales cabe destacar el grupo de los bifosfonatos, los cuales son de gran utilidad en estos pacientes si se considera su potencial capacidad para inhibir la intensa actividad osteoclástica y por tanto disminuir y regular el proceso de recambio óseo.</p><p>A diferencia del tratamiento con otros fármacos, los bifosfonatos logran por lo general una remisión clínica completa del cuadro, circunstancia que se traduce en una normalización de los parámetros bioquímicos así como en una mejoría a nivel de las estructuras histológicas óseas. En el presente trabajo ofrecemos una revisión sobre las características clínicas del cuadro para su adecuado manejo en la clínica, así como una actualización sobre las diferentes alternativas en su diagnóstico y manejo terapéutico centrándonos de modo especial en la terapia con bifosfonatos, esto es, su estructura molecular así como sus principales indicaciones y beneficios derivados de su administración.</p></div><div><p>Paget's disease of bone is characterized by the appearance and development of progressive skeletal deformation due to an accelerated rate of bone resorption coupled with osteoblastic activity of similar or equal intensity. This produces bone formation that is structurally disorganized.</p><p>The parallel development of excessive bone remodelling requires the clinical use of anti-resorptive drugs, such as bisphosphonates. These drugs are very effective in the treatment of patients with Paget's disease because they are able to inhibit overly intense osteoclastic activity, and thus, decrease and regulate the bone turnover process. Unlike other drugs, bisphosphonates generally produce the total remission of symptoms, which means the normalization of biochemical parameters as well as improved bone histology.</p><p>This paper reviews and discusses the symptoms of Paget's disease of bone so that it can be more effectively treated at healthcare facilities. We also discuss the latest diagnostic methods used as well as different treatments for this disease with a special focus on bisphosphonates, particularly, their chemical composition, usage, and benefits derived from administration.</p></div>","PeriodicalId":101109,"journal":{"name":"Revista Espa?ola de Enfermedades Metabólicas óseas","volume":"18 2","pages":"Pages 34-38"},"PeriodicalIF":0.0,"publicationDate":"2009-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1132-8460(09)72052-5","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"120874601","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}